HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.048553v1 49/5/823    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miao, Y. Articles by Quinn, T. P. Search for Related Content PubMed PubMed Citation Articles by Miao, Y. Articles by Quinn, T. P.

²⁰³Pb-Labeled -Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection

¹ Department of Dermatology, University of New Mexico, Albuquerque, New Mexico; ² College of Pharmacy, University of New Mexico, Albuquerque, New Mexico; ³ Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico; ⁴ Department of Veterans Affairs Medical Center, Columbia, Missouri; ⁵ Pacific Northwest National Laboratory, Richland, Washington; ⁶ AlphaMed Inc., Acton, Massachusetts; ⁷ Department of Internal Medicine, University of Missouri, Columbia, Missouri; ⁸ Department of Chemistry, University of Missouri, Columbia, Missouri; ⁹ Department of Biochemistry, University of Missouri, Columbia, Missouri; and ¹⁰ Department of Radiology, University of Missouri, Columbia, Missouri

Correspondence: For correspondence or reprints contact either of the following: Yubin Miao, 2502 Marble NE, MSC09 5360, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131. E-mail: ymiao{at}salud.unm.edu Thomas P. Quinn, 117 Schweitzer Hall, Department of Biochemistry, University of Missouri, Columbia, MO 65211. E-mail: quinnt{at}missouri.edu

Peptide-targeted -therapy with 7.4 MBq of ²¹²Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys^3,4,10,D-Phe⁷,Arg¹¹]-MSH_3–13 (²¹²Pb-DOTA-Re(Arg¹¹)CCMSH) cured 45% of B16/F1 murine melanoma–bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to ²¹²Pb-DOTA-Re(Arg¹¹)CCMSH therapy. The purpose of this study was to evaluate the potential of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH as a matched-pair SPECT agent for ²¹²Pb-DOTA-Re(Arg¹¹)CCMSH. Methods: DOTA-Re(Arg¹¹)CCMSH was labeled with ²⁰³Pb in 0.5 M NH₄OAc buffer at pH 5.4. The internalization and efflux of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH was examined in B16/F1 melanoma–bearing C57 mice. A micro-SPECT/CT study was performed with ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH in a B16/F1 melanoma–bearing C57 mouse at 2 h after injection. Results: ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH was easily prepared in NH₄OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH activity internalized after a 20-min incubation at 25°C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH exhibited a biodistribution pattern similar to that of ²¹²Pb-DOTA-Re(Arg¹¹)CCMSH in B16/F1 melanoma–bearing mice. ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH exhibited a peak tumor uptake of 12.00 ± 3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43 ± 1.12 %ID/g at 48 h after injection. ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. ²⁰³Pb showed 1.6-mm SPECT resolution, which was comparable to ^99mTc. Melanoma lesions were visualized through SPECT/CT images of ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH at 2 h after injection. Conclusion: ²⁰³Pb-DOTA-Re(Arg¹¹)CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for ²¹²Pb-DOTA-Re(Arg¹¹)CCMSH melanoma treatment.

Key Words: molecular imaging • radiopharmaceuticals • peptides • ²⁰³Pb-labeled • melanoma imaging

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				D. Denoyer, I. Greguric, P. Roselt, O. C. Neels, N. Aide, S. R. Taylor, A. Katsifis, D. S. Dorow, and R. J. Hicks High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance J. Nucl. Med., March 1, 2010; 51(3): 441 - 447. [Abstract] [Full Text] [PDF]

				G. Ren, Z. Liu, Z. Miao, H. Liu, M. Subbarayan, F. T. Chin, L. Zhang, S. S. Gambhir, and Z. Cheng PET of Malignant Melanoma Using 18F-Labeled Metallopeptides J. Nucl. Med., November 1, 2009; 50(11): 1865 - 1872. [Abstract] [Full Text] [PDF]